The biotechnology startup Jellatech has entered a strategic partnership with the South Korean medical aesthetics company Hugel to develop and commercialize cell-based human collagen. Jellatech produces bioidentical human collagen by culturing cells from a small skin biopsy in bioreactors, a process that avoids the use of animal sources. This collaboration grants Hugel exclusive global rights to use Jellatech’s collagen for specific aesthetic applications, including skin-boosting products. The agreement marks a significant commercial milestone for Jellatech as it seeks to scale its technology for broader use in medical aesthetics and regenerative medicine. By utilizing cell culture methods, the company aims to provide a consistent, purified alternative to traditional collagen derived from cattle, pigs, or fish, which often faces challenges regarding biological compatibility and environmental impact.
Source: Jellatech Partners with Hugel to Bring Cell-Cultured Human Collagen to Market
